Montril Flash Tablet 4 mg

Montril (Montelukast Sodium 4 mg) is a leukotriene receptor antagonist tablet manufactured by Aristopharma Ltd. Priced at ৳7.00 per tablet, it offers an affordable solution for asthma management and allergic rhinitis treatment. The pack options include strips (৳70.00) and a 3×10 pack (৳210.00), ensuring accessibility for chronic users.

This flash tablet works by blocking cysteinyl leukotriene receptors, reducing airway inflammation. It effectively prevents asthma attacks, exercise-induced bronchoconstriction, and seasonal allergies. Unlike corticosteroids, Montril offers a non-steroidal approach to respiratory care.

Dosage guidelines vary by age:

• Adults: 10 mg once daily
• Children (6-14 years): 5 mg daily
• Infants (6 months-5 years): 4 mg daily

Take tablets whole, with/without food, preferably in the evening or 2 hours before exercise.

Common side effects include headache, nausea, and diarrhea. Rare risks involve neuropsychiatric symptoms like anxiety or tremors. Store below 30°C, protected from moisture. Consult doctors before use during pregnancy or lactation.

As a Montelukast Sodium brand, Montril 4 mg complements Aristopharma’s respiratory care portfolio. Its safety profile makes it suitable for long-term management of chronic respiratory conditions.

Adults & 15+ years: 10 mg once daily. 6-14 years: 5 mg daily. 6 months-5 years: 4 mg daily. Take evening dose for asthma/allergies, 2 hours before exercise. Flash tablet can be taken with/without food. Do not adjust dose without medical advice.

Common: Diarrhoea, fever, gastrointestinal discomfort, headache, nausea, vomiting, skin reactions, upper respiratory tract infection.

Uncommon: Akathisia, anxiety, arthralgia, asthenia, abnormal behavior, depression, dizziness, drowsiness, dry mouth, haemorrhage, irritability, malaise, muscle complaints, oedema, seizure, abnormal sensation, sleep disorders.

Rare: Angioedema, concentration impaired, disorientation, eosinophilic granulomatosis with polyangiitis, erythema nodosum, hallucination, hepatic disorders, memory loss, palpitations, pulmonary eosinophilia, suicidal tendencies, tremor.

Use in pregnancy only if absolutely needed. No fetal harm in animal studies, but human data limited. Avoid during lactation—excreted in breast milk.

Monitor for psychiatric symptoms (anxiety, suicidal thoughts). Not for acute asthma attacks. Use Aristopharma‘s tablet with regular clinical monitoring.

Pediatric dosing varies by age. No dose adjustment needed for elderly or renal/hepatic impairment patients. Use in pregnancy under medical supervision.

There were no adverse experiences in the majority of overdosage reports. The most frequently occurring adverse experiences were consistent with the safety profile of Montril and included abdominal pain, somnolence, thirst, headache, vomiting and psychomotor hyperactivity. In the event of overdose, it is reasonable to employ the usual supportive measures; e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive therapy, if required.